



Unlock Tumor-Derived Signals with Tumor SPARCs™

Liquid Biopsy Solutions for Oncology Drug Development


What Are TumorSPARCs?

TumorSPARCs™ (Selective Protein Affinity Reagent Chemistries) is FYR Bio's proprietary technology designed to capture tumor-derived extracellular vesicle (EV) subpopulations in blood samples across multiple cancer types. Using affinity-based capture reagents optimized to recognize tumor-associated glycan features on EV surfaces, TumorSPARCs preserves intact vesicles for downstream multiomic analysis of protein and nucleic acids.

Tumor SPARCs Advantages

Feature	TumorSPARCs Liquid Biopsy	Tissue Biopsy	Imaging
Non-Invasive	✓	✗	✓
Repeat Monitoring	✓	✗	✓
Molecular Insight	✓	✓	✗

~1,100× Higher Abundance of 183 Oncology-Associated Proteins



Revealing the Next Generation of Oncology Liquid Biopsy

FYR Bio leverages its proprietary TumorSPARCs technology to enrich tumor-derived signals from blood, overcoming signal-to-noise challenges to enable detection of more biomarkers and deeper insights across a broad range of cancers, including brain cancers. This enhanced sensitivity supports more comprehensive molecular profiling from a blood draw, revealing clinically meaningful information that may otherwise remain undetectable and enabling better treatment across the cancer care continuum.

Enriching Tumor-Associated EVs, TumorSPARCs:



Accesses tumor-associated biology from a simple blood draw



Improves detection of tumor-derived EV markers, oncoproteins, and tumor suppressors



Depletes abundant plasma protein background to improve signal-to-noise



Preserves intact vesicles for downstream multiomic analysis



Detects EVs crossing the blood-brain barrier to unlock neuro-oncology insights



Enables repeatable, minimally invasive longitudinal sampling across studies

Partner With Us To Support Drug Development

We partner with pharmaceutical and biotechnology companies to integrate TumorSPARCs across the drug development lifecycle:

Preclinical & Translational

- Biomarker discovery
- Target engagement
- Tumor biology and pathway profiling
- Pharmacodynamic analysis

Clinical Development & Monitoring

- Patient stratification and cohort selection
- Pharmacodynamic and treatment response biomarkers
- Disease detection and monitoring

Connect With and Follow Us

Scan the QR code or contact us directly at bd@fyr.bio to learn more.



Contact: bd@fyr.bio
Visit: www.fyr.bio
LinkedIn: @FYR Bio
Twitter/X: @FYR_Bio

